Apply to trial NCT06413992

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial Cancer. The study will also explore the prevalence of homologous recombination reficiency in Chinese patients with TP-53 mutated endometrial cancer and its therapeutic significance.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening